HR Execs on the Move

Pullman Power

www.pullmanpower.com

 
Pullman Power LLC is a Kansas City, MO-based company in the Manufacturing sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Robert Family Holdings

RFH has been successfully increasing values since our start in 1946. We design, manufacture and deliver products with highly engineered solutions to a wide range of industries. The company has a global presence with set manufacturing locations in five different countries, with a worldwide sales network.

SSI CHUSEI Inc

SSI CHUSEI Inc is a Pasadena, TX-based company in the Manufacturing sector.

Nanovere Technologies

Nanovere Technologies, Inc. is a Brighton, MI-based company in the Manufacturing sector.

Sugar Shack

Sugar Shack is a Westfield, NY-based company in the Manufacturing sector.

enVVeno

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company`s lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe™. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the company is currently waiting for regulatory approval to begin the TAVVE first-in-human trial for enVVe.